Scandinavian ChemoTech

The agreement begins as a rental program, providing the clinic with immediate access to the innovative Tumor-Specific Electroporation (TSE) technology. The program is structured to transition through a lease-to-buy arrangement to a purchase in 2026, ensuring long-term access to cutting-edge treatment capabilities for equine patients.

Training and installation are scheduled to be completed before the end of 2025, enabling the clinic's veterinary teams to begin integrating TSE technology into their oncology services shortly thereafter.

"We are very pleased to see the strong reputation we have built within equine hospitals and universities across Europe now extending into the U.S. market," said Stefan Mohan Frick, CEO of ChemoTech. "This collaboration with one of Kentucky's most respected equine clinics is an important validation of our technology and our mission. We look forward to supporting their team as their experience with TSE grows and are optimistic that this partnership will expand to their other clinics in the future."

Unique Strengths of TSE in Equine Oncology

VQ Animal Care's Tumor-Specific Electroporation (TSE) technology provides several important advantages for treating equine tumors and sarcoids:

• Often performed without general anesthesia, reducing risk and improving safety.
• Tissue-sparing and minimally destructive, resulting in less scarring and better cosmetic and functional outcomes.
• Lower stress for horses thanks to shorter, less invasive procedures and fast recovery.
• More cost-efficient for owners, with fewer resources needed and lower overall treatment costs.
• Accessible in a wide range of clinical settings, as many treatments can be performed with the horse standing under light sedation.

These strengths have made TSE a preferred option in leading European equine hospitals, and its introduction to top U.S. clinics marks an important step in advancing humane and cost-effective cancer care for horses.